JP2023506842A5 - - Google Patents

Info

Publication number
JP2023506842A5
JP2023506842A5 JP2022536699A JP2022536699A JP2023506842A5 JP 2023506842 A5 JP2023506842 A5 JP 2023506842A5 JP 2022536699 A JP2022536699 A JP 2022536699A JP 2022536699 A JP2022536699 A JP 2022536699A JP 2023506842 A5 JP2023506842 A5 JP 2023506842A5
Authority
JP
Japan
Prior art keywords
sequence
pharmaceutical composition
molecule
wiz
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022536699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506842A (ja
JP7846007B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/001098 external-priority patent/WO2021123920A1/en
Publication of JP2023506842A publication Critical patent/JP2023506842A/ja
Publication of JP2023506842A5 publication Critical patent/JP2023506842A5/ja
Application granted granted Critical
Publication of JP7846007B2 publication Critical patent/JP7846007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022536699A 2019-12-18 2020-12-16 異常ヘモグロビン症の治療用組成物及び方法 Active JP7846007B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962950048P 2019-12-18 2019-12-18
US201962950025P 2019-12-18 2019-12-18
US62/950,048 2019-12-18
US62/950,025 2019-12-18
PCT/IB2020/001098 WO2021123920A1 (en) 2019-12-18 2020-12-16 Compositions and methods for the treatment of hemoglobinopathies

Publications (3)

Publication Number Publication Date
JP2023506842A JP2023506842A (ja) 2023-02-20
JP2023506842A5 true JP2023506842A5 (https=) 2024-10-16
JP7846007B2 JP7846007B2 (ja) 2026-04-14

Family

ID=74701511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022536699A Active JP7846007B2 (ja) 2019-12-18 2020-12-16 異常ヘモグロビン症の治療用組成物及び方法

Country Status (5)

Country Link
US (1) US20230279394A1 (https=)
EP (1) EP4077676A1 (https=)
JP (1) JP7846007B2 (https=)
CN (1) CN115176005A (https=)
WO (1) WO2021123920A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250179531A1 (en) * 2022-02-25 2025-06-05 Vor Biopharma Inc. Compositions and methods for homology-directed repair gene modification
CN116445402B (zh) * 2023-05-09 2025-04-25 中国科学院生态环境研究中心 红系祖细胞的扩增培养基、扩增培养方法及应用
US12385408B1 (en) * 2024-01-26 2025-08-12 Rtx Corporation Life and performance improvement trenches

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
DK0642356T3 (da) 1992-05-05 2003-08-04 Aeres Biomedical Ltd Antistoffer mod P-selectin og deres anvendelser
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
AR013269A1 (es) 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
CA2433680A1 (en) 2000-12-28 2002-08-01 Gregory M Arndt Double-stranded rna-mediated gene suppression
EP1709195B1 (en) 2003-12-19 2014-01-22 Novartis Vaccines and Diagnostics, Inc. Cell transfecting formulations of small interfering rna, related compositions and methods of making and use
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
HUE041957T2 (hu) 2006-12-01 2019-06-28 Novartis Ag Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
WO2009108274A2 (en) * 2008-02-26 2009-09-03 The University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CA3009891C (en) 2009-12-23 2020-09-15 Novartis Ag Lipids, lipid compositions, and methods of using them
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
MX2013002332A (es) 2010-08-31 2013-03-18 Novartis Ag Lipidos apropiados para suministro liposomal del arn que codifica la proteina.
EP4115875A1 (en) 2011-07-06 2023-01-11 GlaxoSmithKline Biologicals S.A. Liposomes having useful n:p ratio for delivery of rna molecules
PT2768942T (pt) 2011-10-17 2020-01-21 Massachusetts Inst Technology Entrega intracelular
US9394547B2 (en) 2012-01-03 2016-07-19 City University Of Hong Kong Method and apparatus for delivery of molecules to cells
WO2013103467A1 (en) 2012-01-06 2013-07-11 Alcon Research, Ltd. Interfering rna delivery system and uses thereof
EP2807165B1 (en) 2012-01-27 2019-05-15 Université de Montréal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
MX367100B (es) * 2012-02-17 2019-08-05 The Children´S Hospital Of Philadelphia Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos.
US10227610B2 (en) 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
CN107879960B (zh) 2013-03-08 2021-06-22 诺华股份有限公司 用于传递活性成分的脂质和脂质组合物
DK2970948T3 (en) 2013-03-15 2019-04-08 Glaxosmithkline Biologicals Sa METHODS OF RNA PURIFICATION
WO2014150256A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
KR102243597B1 (ko) 2013-08-16 2021-04-26 메사추세츠 인스티튜트 오브 테크놀로지 세포로의 선택적 물질 전달
EP3083556B1 (en) 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2015157070A2 (en) * 2014-04-09 2015-10-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating cystic fibrosis
WO2018071871A1 (en) 2016-10-13 2018-04-19 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
WO2018091971A1 (en) * 2016-11-15 2018-05-24 Genomic Vision Method for the monitoring of modified nucleases induced-gene editing events by molecular combing
US20180305719A1 (en) * 2017-04-19 2018-10-25 The Board Of Trustees Of The University Of Illinois Vectors For Integration Of DNA Into Genomes And Methods For Altering Gene Expression And Interrogating Gene Function
CN111655271B (zh) * 2017-12-28 2025-09-23 隆萨销售股份公司 用于免疫肿瘤学和抗炎疗法的外来体
US20190345516A1 (en) * 2018-03-12 2019-11-14 Musc Foundation For Research Development Methods for treating eye disease

Similar Documents

Publication Publication Date Title
AU2019226001B2 (en) CAMK2D antisense oligonucleotides and uses thereof
US11932856B2 (en) RNA targeting of mutations via suppressor tRNAs and deaminases
US10369232B2 (en) Allele selective gene editing and uses thereof
JP2024038326A5 (https=)
AU2020313143A1 (en) Targeted RNA editing by leveraging endogenous adar using engineered RNAs
JP2023506842A5 (https=)
WO2015153791A1 (en) Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2)
JP7546295B2 (ja) ヒトアンジェルマン症候群において父方ube3a遺伝子発現を復活させるための組成物および方法
EP3758714A1 (en) Methods and compositions for treating angelman syndrome
JP2024119830A5 (https=)
CN113994009B (zh) 用于修饰scn9a或scn10a基因的基因编辑系统及其使用方法
JP2022501044A5 (https=)
US20200263206A1 (en) Targeted integration systems and methods for the treatment of hemoglobinopathies
JP2021525531A5 (https=)
JP2021534796A5 (https=)
AU2017231865B2 (en) Allele-specific gene suppression
JP2022548320A (ja) アポリポタンパク質b(apob)遺伝子発現をモジュレートするための組成物および方法
US20230332150A1 (en) shRNA TARGETING SNORD115 LOCATIONS TO RESTORE PATERNAL UBE3A GENE EXPRESSION IN ANGELMAN SYNDROME
CN115916975A (zh) 靶向mitf基因的核酸分子及其用途
JP2022508835A5 (https=)
CN112779252B (zh) 靶向SMN2启动子区MeCP2结合的关键甲基化区域的反义寡核苷酸
CA3017326C (en) Allele-specific gene suppression
WO2025196338A1 (en) Methods and compositions for the treatment of autosomal dominant polycystic kidney disease
WO2024254244A2 (en) RNAi TARGETING HNRNPH2 MISSENSE MUTATIONS FOR TREATMENT OF BAIN SYNDROME
KR20230123926A (ko) Dlx2 벡터